Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903971 | 0.90 | HCRTR2 (0.59) | HCRTR2HCRTR1 | |
| SCHEMBL13789791 | 0.86 | HCRTR2 (0.77) | HCRTR2HCRTR1 | |
| SCHEMBL8217485 | 0.83 | HCRTR1 (0.59) | HCRTR2HCRTR1 | |
| SCHEMBL2905754 | 0.78 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL2897908 | 0.75 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL2904888 | 0.73 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL2903983 | 0.73 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL13208607 | 0.72 | HCRTR1 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL8218996 | 0.68 | HCRTR2 (0.79) | HCRTR2HCRTR1 | |
| SCHEMBL7457811 | 0.67 | CYP11B1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | claimed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | claimed |
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.